BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
More Than 110 New Species Discovered In Deep Waters Off Australia - 2Extravagance SUVs for Seniors: Solace, Innovation, and Security
- 3Moderna to complete US mRNA manufacturing network with $140 million investment
- 4The Force of Systems administration: Individual Examples of overcoming adversity
- 5Israeli girl suffers cardiac arrest during sirens in Safed, hospitalized in serious condition
- IDF strikes terror infrastructure across Iran, attack reported on Kashan airport
- Sintana Energy flags major resource upgrade at Namibia oil discovery
- Presenting Nintendo's New Pastel Bliss Con Tones for Switch Gamers: 3 Smart Choices
- Here's what the Artemis 2 astronauts will be doing on each day of NASA's historic moon mission
- A somber Thor is returning for 'Avengers: Doomsday': Watch the dread-filled teaser
- Why is Jerome Powell being investigated? Making sense of the DOJ's probe into the Federal Reserve chair.
- 4 Coolers for Present day Kitchens
- Civilian toll mounts in Iran as war presses on
- Architect Frank Gehry has died: See his most iconic buildings
